OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Short-term cost-effectiveness analysis of tirzepatide for the treatment of type 2 diabetes in the United States
Xiaotong Zhang, Carrie McAdam Marx
Journal of Managed Care & Specialty Pharmacy (2023) Vol. 29, Iss. 3, pp. 276-284
Open Access | Times Cited: 11
Xiaotong Zhang, Carrie McAdam Marx
Journal of Managed Care & Specialty Pharmacy (2023) Vol. 29, Iss. 3, pp. 276-284
Open Access | Times Cited: 11
Showing 11 citing articles:
Glycemic Control, Weight Management, Cardiovascular Safety, and Cost-Effectiveness of Semaglutide for Patients with Type 2 Diabetes Mellitus: A Rapid Review and Meta-analysis of Real-World Studies
Sihua Wang, Sheng Wang, Yan Wang, et al.
Diabetes Therapy (2024) Vol. 15, Iss. 2, pp. 497-519
Open Access | Times Cited: 8
Sihua Wang, Sheng Wang, Yan Wang, et al.
Diabetes Therapy (2024) Vol. 15, Iss. 2, pp. 497-519
Open Access | Times Cited: 8
Therapeutic Advances in Obesity: How Real-World Evidence Impacts Affordability Beyond Standard of Care
Dimitrios Patoulias, Theocharis Koufakis, Ieva Ruža, et al.
Pragmatic and Observational Research (2024) Vol. Volume 15, pp. 139-149
Open Access | Times Cited: 5
Dimitrios Patoulias, Theocharis Koufakis, Ieva Ruža, et al.
Pragmatic and Observational Research (2024) Vol. Volume 15, pp. 139-149
Open Access | Times Cited: 5
Appropriate use of the fixed-dose, extended-release combination of naltrexone and bupropion as treatment for obesity in primary care
Ethan Lazarus
Obesity Pillars (2025) Vol. 14, pp. 100170-100170
Open Access
Ethan Lazarus
Obesity Pillars (2025) Vol. 14, pp. 100170-100170
Open Access
Semaglutide vs Revisional Bariatric Surgery: What Is the Best Option for Suboptimal Clinical Response or Recurrent Weight Gain After MBS?
Yeisson Rivero-Moreno, Arturo Estrada, Nawaf Hindosh, et al.
Research Square (Research Square) (2025)
Closed Access
Yeisson Rivero-Moreno, Arturo Estrada, Nawaf Hindosh, et al.
Research Square (Research Square) (2025)
Closed Access
Cost‐utility analysis and drug pricing for tirzepatide for type 2 diabetes in the Chinese market compared with semaglutide
Shanshan Hu, Chenyang Shi, Yuhang Ma, et al.
Diabetes Obesity and Metabolism (2024) Vol. 26, Iss. 8, pp. 3176-3190
Closed Access | Times Cited: 2
Shanshan Hu, Chenyang Shi, Yuhang Ma, et al.
Diabetes Obesity and Metabolism (2024) Vol. 26, Iss. 8, pp. 3176-3190
Closed Access | Times Cited: 2
Tirzepatide-Induced Gastrointestinal Manifestations: A Systematic Review and Meta-Analysis
Hani Raka Karrar, Mahmoud Ismail Nouh, Yousef Ismail Nouh, et al.
Cureus (2023)
Open Access | Times Cited: 6
Hani Raka Karrar, Mahmoud Ismail Nouh, Yousef Ismail Nouh, et al.
Cureus (2023)
Open Access | Times Cited: 6
The Effects of Tirzepatide on Lipid Profile: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
Muhammad Umar Mahar, Omar Mahmud, Salaar Ahmed, et al.
Journal of Obesity & Metabolic Syndrome (2024) Vol. 33, Iss. 4, pp. 348-359
Open Access | Times Cited: 1
Muhammad Umar Mahar, Omar Mahmud, Salaar Ahmed, et al.
Journal of Obesity & Metabolic Syndrome (2024) Vol. 33, Iss. 4, pp. 348-359
Open Access | Times Cited: 1
Cost per Patient Achieving Treatment Targets and Number Needed to Treat with Tirzepatide Versus Semaglutide 1 mg in Patients with Type 2 Diabetes in the United States
Reema Mody, Kellie Meyer, Jennifer M. Ward, et al.
Diabetes Therapy (2023) Vol. 14, Iss. 12, pp. 2045-2055
Open Access | Times Cited: 2
Reema Mody, Kellie Meyer, Jennifer M. Ward, et al.
Diabetes Therapy (2023) Vol. 14, Iss. 12, pp. 2045-2055
Open Access | Times Cited: 2
Revolutionizing diabetes care: unveiling tirzepatide’s potential in glycemic control and beyond
Aayushi Sood, Purnoor Kaur, Omar Syed, et al.
Expert Review of Clinical Pharmacology (2024) Vol. 17, Iss. 3, pp. 235-246
Closed Access
Aayushi Sood, Purnoor Kaur, Omar Syed, et al.
Expert Review of Clinical Pharmacology (2024) Vol. 17, Iss. 3, pp. 235-246
Closed Access
Tirzepatide: unveiling a New Dawn in Dual-Targeted diabetes and obesity management
Syed Arman Rabbani, Mohamed El‐Tanani, Ismail Matalka, et al.
Expert Review of Endocrinology & Metabolism (2024) Vol. 19, Iss. 6, pp. 487-505
Closed Access
Syed Arman Rabbani, Mohamed El‐Tanani, Ismail Matalka, et al.
Expert Review of Endocrinology & Metabolism (2024) Vol. 19, Iss. 6, pp. 487-505
Closed Access
An exploratory analysis of glucagon‐like peptide‐1 (GLP ‐1) agonists and biosimilars: A literature review
Jimmy Wen, Adam A Razick, Christiane How‐Volkman, et al.
Diabetes Obesity and Metabolism (2024)
Closed Access
Jimmy Wen, Adam A Razick, Christiane How‐Volkman, et al.
Diabetes Obesity and Metabolism (2024)
Closed Access
